CONSUMER RIGHTS IN HORMONE-RELATED THERAPIES

1. INTRODUCTION

Hormone-related therapies involve medical treatments designed to regulate, replace, suppress, or modify hormonal activity within the human body. These therapies include hormone replacement therapy (HRT), thyroid hormone treatment, insulin-related endocrine management, testosterone therapy, oestrogen therapy, progesterone treatment, growth hormone therapy, and gender-affirming hormone treatment.

Although these interventions can provide significant medical benefits, inappropriate prescriptions, incorrect dosages, inadequate monitoring, misleading advertisements, and failure to disclose treatment risks may cause serious physical and psychological consequences.

Consumer protection law safeguards patients against deficient medical services, unfair commercial practices, misleading treatment claims, and professional negligence. In India, the Consumer Protection Act, 2019, provides an important legal framework for protecting individuals receiving hormone-related healthcare services.

2. LEGAL FRAMEWORK GOVERNING CONSUMER RIGHTS

A. CONSUMER PROTECTION ACT, 2019

Sections 2(7), 2(11), 2(42), and 2(47) address consumer status, deficiency in service, services, and unfair trade practices. Patients receiving qualifying paid medical services can seek remedies for deficient treatment and misleading representations.

B. ARTICLE 21 OF THE CONSTITUTION

Article 21 protects life, dignity, bodily integrity, and personal autonomy. Patients have an important right to participate in decisions concerning hormone-related medical interventions.

C. MEDICAL PROFESSIONAL STANDARDS

Medical practitioners must exercise reasonable professional care in diagnosis, prescription, dosage selection, monitoring, and treatment management.

D. PATIENT CONSENT AND CONFIDENTIALITY

The Samira Kohli principles require voluntary and adequately informed consent. Medical practitioners must also protect confidential medical information, including sensitive hormonal and reproductive health records.

3. MAJOR CONSUMER RIGHTS IN HORMONE-RELATED THERAPIES

A. RIGHT TO INFORMED CONSENT

Patients must receive understandable information concerning treatment objectives, expected benefits, material risks, alternatives, and possible consequences of refusing treatment.

B. RIGHT TO SAFE MEDICAL TREATMENT

Patients are entitled to reasonably competent diagnosis, appropriate prescriptions, correct medication administration, and clinically necessary monitoring.

C. RIGHT TO ACCURATE INFORMATION

Healthcare providers must not make misleading claims about guaranteed hormonal balance, permanent rejuvenation, fertility enhancement, or other unsupported therapeutic benefits.

D. RIGHT TO MEDICAL RECORDS

Patients should have access to relevant prescriptions, laboratory investigations, treatment histories, and medical reports, subject to applicable legal requirements.

E. RIGHT TO PRIVACY AND CONFIDENTIALITY

Hormonal information may reveal reproductive status, endocrine conditions, and other sensitive medical details. Healthcare institutions must protect such information against unauthorised disclosure.

F. RIGHT TO COMPENSATION

Patients may seek compensation where negligent hormone administration, deficient monitoring, or misleading healthcare services cause legally established injury or loss.

4. IMPORTANT CASE LAWS

1. INDIAN MEDICAL ASSOCIATION v. V.P. SHANTHA (1995) — DIRECT AUTHORITY

The Supreme Court recognised that medical services provided for consideration generally fall within consumer protection legislation, subject to specified exceptions.

Application: Patients receiving paid hormone-related medical services may approach consumer commissions for deficiency in service.

2. SAMIRA KOHLI v. DR. PRABHA MANCHANDA (2008) — DIRECT GENERAL AUTHORITY

The Supreme Court established that medical consent must be voluntary, competent, and based on adequate information. Consent for one procedure cannot automatically authorise a substantially different procedure.

Application: Patients undergoing hormone replacement or reproductive hormone interventions must receive appropriate treatment-specific information and provide valid consent.

3. JACOB MATHEW v. STATE OF PUNJAB (2005) — ANALOGOUS AUTHORITY

The Supreme Court explained the professional standard of care required to establish medical negligence.

Application: Unreasonable hormone prescriptions, negligent dosage decisions, and failure to follow accepted monitoring standards may attract liability.

4. KUSUM SHARMA v. BATRA HOSPITAL AND MEDICAL RESEARCH CENTRE (2010) — ANALOGOUS AUTHORITY

The Supreme Court clarified the principles governing medical negligence and emphasised that unsuccessful treatment does not automatically establish negligence.

Application: Hormone therapy complaints must be assessed against accepted professional standards and the circumstances of treatment.

5. SAVITA GARG v. DIRECTOR, NATIONAL HEART INSTITUTE (2004) — ANALOGOUS AUTHORITY

The Supreme Court discussed evidentiary responsibilities and institutional accountability in medical negligence proceedings.

Application: Hospitals should maintain prescriptions, laboratory reports, dosage records, and monitoring documentation to establish the quality of treatment.

6. NATIONAL LEGAL SERVICES AUTHORITY v. UNION OF INDIA (2014) — ANALOGOUS CONSTITUTIONAL AUTHORITY

The Supreme Court recognised transgender persons' constitutional rights to dignity, identity, and personal autonomy.

Application: Its constitutional principles are relevant to respecting patient autonomy and dignity in gender-affirming healthcare, including decisions concerning hormone-related treatment.

5. SPECIFIC CONSUMER PROTECTION ISSUES

A. HORMONE REPLACEMENT THERAPY: Patients should receive information about material cardiovascular, thrombotic, reproductive, and other treatment-related risks, as applicable.

B. THYROID HORMONE TREATMENT: Incorrect prescribing or inadequate monitoring may result in preventable complications.

C. TESTOSTERONE AND OESTROGEN THERAPY: Healthcare providers should explain relevant contraindications, foreseeable adverse effects, and monitoring requirements.

D. GROWTH HORMONE TREATMENT: Patients should receive accurate information concerning approved indications, limitations, and potential adverse effects.

E. GENDER-AFFIRMING HORMONE TREATMENT: Providers should respect autonomy, confidentiality, informed consent, and individual treatment requirements.

6. PRACTICAL LEGAL COMPLIANCE REQUIREMENTS

Healthcare institutions should:

Obtain appropriate informed consent before treatment.

Verify medical indications and relevant patient history.

Provide accurate information about treatment risks.

Maintain prescription and laboratory records.

Conduct clinically appropriate follow-up monitoring.

Protect confidential hormonal and reproductive health information.

Establish transparent patient grievance mechanisms.

Avoid misleading advertisements and unsupported therapeutic guarantees.

7. CONCLUSION

Consumer rights in hormone-related therapies protect patients against negligent treatment, misleading medical claims, inadequate disclosure, and deficient healthcare services. The Consumer Protection Act, 2019, provides remedies for qualifying deficiencies, while judicial decisions such as V.P. Shantha, Samira Kohli, and Jacob Mathew establish important principles governing medical accountability, informed consent, and professional negligence. Healthcare providers must therefore ensure transparent communication, appropriate monitoring, confidentiality, and respect for patient autonomy throughout hormone-related treatment.